One-year clinical follow-up and outcomes in patients after drug-eluting stent implantation for unprotected left main coronary stenosis: A single center study from Turkey

Objective. Although there are many randomized trials about unprotected left main percutaneous coronary intervention (ULMPCI), there are few data from Turkey. Therefore, we aimed to present the first data about ULMPCI, determine SYNTAX and EuroSCORE II scores, clinical and demographic data of patients; monitor mortality, morbidity and need for revascularization during 1-year follow-up. Methods and Results. A retrospective 1-year follow-up study of 53 patients who underwent ULMPCI was conducted. Primary endpoint was occurrence of major adverse cardiovascular and cerebrovascular events (MACCE), based on sudden cardiac death (SCD), myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), stent thrombosis and stroke. Complete revascularization rate was 100%. At 1- year follow-up of the patients, acute coronary syndrome and related cardiac death occurred in 1 (1.9%) of the patients at 8 months, and 1 (1.9%) patient developed restenosis at 9 months. The rate of life without MACCE was 96.2%. A comparison of MACCE rates between diabetic and nondiabetic patients revealed MACCE occurred in 2 patients with diabetes, but this was not statistically significant (p = 0.111). One of these patients was in the low–middlerisk group according to SYNTAX score and the other was in the high-risk group (p = 0.216). Conclusions. In selected patient groups with left main coronary artery disease (patients with low–middle SYNTAX score and high risk of coronary artery bypass grafting surgery, CABG), PCI is a safe and effective treatment option alternative to CABG with high process success and low MACCE rate.